If approved by the EC, Wainzua would be the only approved medicine for the treatment of ATTRv-PN in the EU able to be self-administered with an autoinjector on a monthly basis. “Due to the progressive ...

(Alliance News) - AstraZeneca PLC on Monday said its Wainzua treatment has been been recommended for EU approval to treat adult patients with polyneuropathy associated with hereditary ...

First and only NMPA-approved treatment for patients with CIDP in China Second VYVGART Hytrulo indication approved in China November 11, 2024 – ...

AstraZeneca and Ionis are set fair for EU approval of Wainzua, their treatment for polyneuropathy associated with transthyretin-mediated amyloidosis (ATTR), after the EMA's human medicines ...

000mg (5.6ml)/vial [efgartigimod alfa injection (subcutaneous injection)] for the treatment of adult patients with chronic inflammatory demyelinating polyneuropathy (CIDP). VYVGART Hytrulo is ...

000mg (5.6ml)/vial [Efgartigimod Alfa Injection (Subcutaneous Injection)] for the treatment of adult patients with chronic ...

000mg (5.6ml)/vial [Efgartigimod Alfa Injection (Subcutaneous Injection)] for the treatment of adult patients with chronic inflammatory demyelinating polyneuropathy (CIDP). VYVGART Hytrulo is ...

Having additional amyloidosis treatment options designed to reduce the production of TTR protein at its ... Ruud Dobber, Executive Vice-President, BioPharmaceuticals Business Unit, AstraZeneca, said: ...